期刊文献+

L-型钙离子通道抑制剂药效团模型的构建 被引量:5

Pharmacophore model construction of L-type calcium channel antagonists
下载PDF
导出
摘要 目的构建L-型钙离子通道抑制剂的药效团模型,为从中药化学成分中发现具有钙离子通道抑制作用的成分提供了新的方法,同时为先导物改造成为活性较好的钙离子通道抑制剂提供思路。方法以来源于NCBI数据库中对新西兰兔心脏L-型钙离子通道具有抑制作用的12个化合物为研究对象,利用HipHop定性药效团模型构建方法,建立L-型钙离子通道拮抗剂的药效团模型,利用数据库搜索方法对药效团模型进行优劣评价。结果获得最优药效团模型具有以下几个特征:2个氢键受体和4个疏水基团,其综合评价指数CAI为2.78。结论构建的定性药效团具有一定的可靠性,可用于开展活性化合物筛选和指导先导化合物的结构改造,有助于指导发现中药中的L-型钙离子通道阻滞剂。 Objective This study was amid to construct a pharmacophore model of L-type calcium channel antagonists in the application of a approach for discovering novel L-type calcium channel antagonists from leading compounds by screening traditional Chinese medicine(TCM)database.Methods Qualitative hypotheses were generated by HipHop separately on the basis of 12 compounds with antagonistic action on L-type calcium channel expressed in rabbit cardiac muscle.Database searching method was used to evaluate the hypotheses.Results The results showed that optimal qualitative hypothesis is with certain features,i.e.two hydrogen-bond acceptors,four hydrophobic groups,and the CAI value of 2.78.Conclusion It was concluded that the pharmacophores are reliable and can be used to screen database for novel L-type calcium channel antagonists.
机构地区 北京中医药大学
出处 《西北药学杂志》 CAS 2015年第2期173-176,共4页 Northwest Pharmaceutical Journal
基金 国家自然科学基金(编号:81173522) 北京中医药大学自主课题(编号:2014-JYBZZ-XS-107)
关键词 L-型钙离子通道抑制剂 定性药效团 心血管疾病 中药 化学成分 L-type calcium channel antagonist qualitative hypotheses cardiovascular disease traditional Chinese medicine chemical constituents
  • 相关文献

参考文献8

二级参考文献96

共引文献62

同被引文献49

  • 1肖东琼,秦玲.姜黄与高脂血症[J].中西医结合心脑血管病杂志,2007,5(9):854-856. 被引量:12
  • 2Huang J ,I)orsey J ,Chuikov S,et al. G9a and Glp meth- ylate lysine 373 in the tumor suppressorp53[J]. J Biol Chem,2010,285(13) :9636-9641.
  • 3Tachibana M, Sugimoto K, Nozaki M, et al. G9a histone methyltransferase plays adominant role in euehromatic histone H3 lysine 9 methylation and is essential forearly embryogenesis [J]. Genes Dev, 2002, 16 (14) .. 1779-1791.
  • 4Thomas L R, Miyashita H,Cobb R M, et al. Functional analysis of histone methyl-transferase G9a in B and T lymphocytes[J]. J Immunol, 2008,181 : 485-493.
  • 5Lehnertz B, Zorthrop J P, Antignano F, et al. Activating and inhibitory functions for the histone lysine methyl- transferase G9a in T helper cell differentiation and function[J]. J Exp Med, 2010,207 .. 915-922.
  • 6Schaefer A, Sampath S C, Intrator A, et al. Control of cognition and adaptive behavior by the GLP/G9a epige- netic suppressor complex [-J-]. Neuron, 2009, 64:678 -691.
  • 7Kirmizis A,Bartley S M,Farnham A P J. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy [J]. Mol Cancer Ther,2003,12 (1) : 113-121.
  • 8Shinkai Y, Tachibana A M. H3K9 methyhransferase G9a and the related molecule GLP[J]. Genes Dev, 2011,25 (8) :781-788.
  • 9Yuan Y,Wamg Q,Paulk J,et al. A small-molecule probe of histone methyltrans-ferase G9a induces cellular senescence in pancreatic adenocarcinoma [J]. ACS Chem Biol, 2012,7(7) :1152-1157.
  • 10Kubicek S, O' Sullivan R J, August E M, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase [J]. Mol Cell, 2007, 25: 473-481.

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部